Undisclosed Program(s)

About Trace Neuroscience

Trace Neuroscience is an early-stage, private biotech leveraging a novel RNA-targeting platform to address neurodegenerative diseases. The company's core strategy involves using engineered RNA molecules to precisely modulate gene expression within specific, disease-relevant cell types in the brain, such as microglia. While still in the pre-clinical research and discovery phase, Trace is positioning itself at the intersection of two high-potential fields: neuroscience and RNA therapeutics. Its success hinges on validating its platform and advancing its initial programs toward clinical development.

About PriveBio

PriveBio is a private, preclinical-stage biotech founded in 2018 and based in Cambridge, Massachusetts. The company leverages a proprietary platform that mines extensive human proteo-genomic data to discover novel therapeutic targets involved in metabolic dysfunction and fibro-inflammation. Its pipeline is aimed at addressing significant unmet needs in the interconnected cardiorenal metabolic disease space, including obesity, heart failure, MASH, and CKD. As a pre-revenue company, it is positioned to advance its lead programs toward clinical development, capitalizing on the growing understanding of metabolic disease mechanisms.

About 4M Therapeutics

4M Therapeutics is a private, preclinical-stage biotech focused on central nervous system (CNS) disorders. Its core strategy involves using a human brain cell platform to discover and develop small molecules targeting neuroplasticity, neurogenesis, and neuroinflammation. The lead program, 4MT2001, is a GSK3β inhibitor positioned as a safer alternative to lithium for bipolar disorder, with a broader pipeline targeting agitation in Alzheimer's and neurodegeneration. The company is led by an experienced team with strong academic and industry backgrounds.

About 4M Therapeutics

4M Therapeutics is a private, preclinical-stage biotech focused on central nervous system (CNS) disorders. Its core strategy involves using a human brain cell platform to discover and develop small molecules targeting neuroplasticity, neurogenesis, and neuroinflammation. The lead program, 4MT2001, is a GSK3β inhibitor positioned as a safer alternative to lithium for bipolar disorder, with a broader pipeline targeting agitation in Alzheimer's and neurodegeneration. The company is led by an experienced team with strong academic and industry backgrounds.

About Numerion Labs

Numerion Labs is an AI-driven drug discovery company building a 'superpowered AI drug hunter' platform to radically improve the identification of novel small-molecule therapeutics. Its core technology, comprising the COSMOS foundation model, APEX enumerator, and EXPO optimization algorithms, claims to operate in a chemical space 10,000x larger than competitors with dramatically higher screening efficiency. The company is privately held, pre-revenue, and is advancing internal programs in immune and inflammatory diseases while being guided by a leadership team and board with extensive biopharma and venture capital experience.

About Sound Biologics

Sound Biologics is a clinical-stage biotech leveraging its proprietary MabPair and Bispecific platforms to create novel antibody combination therapies. The company's lead immuno-oncology program has reached patients in China, with additional programs advancing in inflammation and neurology. Sound Biologics aims to improve therapeutic efficacy and accessibility by streamlining combination treatments into single, manufacturable drug products.

About Sound Biologics

Sound Biologics is a clinical-stage biotech leveraging its proprietary MabPair and Bispecific platforms to create novel antibody combination therapies. The company's lead immuno-oncology program has reached patients in China, with additional programs advancing in inflammation and neurology. Sound Biologics aims to improve therapeutic efficacy and accessibility by streamlining combination treatments into single, manufacturable drug products.

About Empyrean Neuroscience

Empyrean Neuroscience is pioneering a novel approach to drug discovery by genetically engineering fungi and plants to create new small molecule therapeutics for severe neurological and neuropsychiatric disorders. The company has built what it claims is the first and only platform capable of this specific application of genetic engineering, combining capabilities in bioinformatics, transformation, and regeneration. Founded in 2021 and based in London with an additional office in Cambridge, UK, and an operational presence in New York, Empyrean is a private, pre-clinical stage company focused on translating its platform into a pipeline of first-in-class human therapeutics. Its strategy targets a significant gap in treatment options for debilitating conditions where current therapies are often inadequate.

Therapeutic Areas